Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Common Equity (2021 - 2026)

HeartSciences' Common Equity history spans 6 years, with the latest figure at $2.7 million for Q1 2026.

  • For Q1 2026, Common Equity rose 48.44% year-over-year to $2.7 million; the TTM value through Jan 2026 reached $2.7 million, up 48.44%, while the annual FY2025 figure was $205171.0, 97.2% down from the prior year.
  • Common Equity reached $2.7 million in Q1 2026 per HSCS's latest filing, down from $4.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $8.6 million in Q1 2024 to a low of -$6.1 million in Q2 2022.
  • Average Common Equity over 5 years is $1.7 million, with a median of $1.8 million recorded in 2025.
  • Peak YoY movement for Common Equity: crashed 252.37% in 2023, then surged 3447.59% in 2024.
  • A 5-year view of Common Equity shows it stood at $1.1 million in 2022, then plummeted by 252.37% to -$1.6 million in 2023, then surged by 343.48% to $4.0 million in 2024, then increased by 4.13% to $4.2 million in 2025, then crashed by 36.59% to $2.7 million in 2026.
  • Per Business Quant, the three most recent readings for HSCS's Common Equity are $2.7 million (Q1 2026), $4.2 million (Q4 2025), and $3.1 million (Q3 2025).